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Abstract
Bacterial genomes encode the biosynthetic potential to produce hundreds of thousands of complex 
molecules with diverse applications, from medicine to agriculture and materials. Economically 
accessing the potential encoded within sequenced genomes promises to reinvigorate waning drug 
discovery pipelines and provide novel routes to intricate chemicals. This is a tremendous 
undertaking, as the pathways often comprise dozens of genes spanning as much as 100+ kiliobases 
of DNA, are controlled by complex regulatory networks, and the most interesting molecules are 
made by non-model organisms. Advances in synthetic biology address these issues, including 
DNA construction technologies, genetic parts for precision expression control, synthetic regulatory 
circuits, computer aided design, and multiplexed genome engineering. Collectively, these 
technologies are moving towards an era when chemicals can be accessed en mass based on 
sequence information alone. This will enable the harnessing of metagenomic data and massive 
strain banks for high-throughput molecular discovery and, ultimately, the ability to forward design 
pathways to complex chemicals not found in nature.
Introduction
Natural products (NPs) are specialized metabolites produced by plants, animals, and 
microorganisms with diverse chemical structures and biological activities. These molecules 
are valuable in the clinical setting, with half of small molecule drugs approved during the 
past three decades being derived from NPs1. While NPs are prevalent in the treatment of 
infection2, cancer3, and as immunosuppressive agents4, they have also made it into 
commercial products as antivirals, anthelmintics, enzyme inhibitors, nutraceuticals, 
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polymers, surfactants, bioherbicides, and vaccines5. In many NP-producing organisms, all of 
the genes required for regulation, biosynthesis, export, and self-resistance are co-localized in 
the genome in compact ‘biosynthetic gene clusters’ (BGCs) (Figure 1a).
Claims that natural products are an inexhaustible resource6 are based on the disparity 
between the staggering biological and chemical diversity on the planet and the relatively 
low-throughput methods currently available to characterize these compounds. In the coming 
decades, advances in technology will close this gap and allow for a more systematic 
characterization of global NP production. Improving bioinformatic methods, combined with 
the dramatic rise in sequenced genomes, is shedding light on the potential number of 
undiscovered natural products (Figure 1b)7–17. In Streptomyces alone, conservative 
estimates put the number of natural products at 150,000, of which <5% have been 
discovered18. Bioinformatic investigations of hundreds of genomes across genera estimate 
that there are 100,000s of NPs19, and the inclusion of less-studied classes, such as 
saccharides and lipids, substantially add to the number of molecules12.
Currently, our ability to mine bacterial genomes to produce NPs is unable to keep pace with 
the identification of new BGCs by DNA sequencing and bioinformatics. However, the cost 
of DNA sequencing and synthesis continues to drop (Figure 1c) and future advances are 
projected to quickly make it possible to build the DNA for many pathways. This leaves 
design as the biggest remaining issue, where it is still challenging to rationally compose a 
DNA sequence for a large pathway that will be functional in a model production host. 
Engineering NP biosynthesis is still difficult for several reasons. Factors like transcription, 
translation, protein-protein interactions, cofactor and precursor availability, export, and self-
resistance all need to be accounted for in a final production strain. In addition, many of the 
organisms that harbor these BGCs are difficult to manipulate or cultivate20,21 and the 
transfer of a BCG to a new host, for which there are successful examples22, is by no means 
trivial.
The goal of this review is to highlight emerging technologies relevant to engineering multi-
gene systems with a special focus on the application of methods from synthetic biology to 
the engineering of biosynthetic pathways and NP-producing organisms. Many of these 
technologies were developed in model lab organisms like E. coli or S. cerevisiae, so when 
relevant, technical difficulties associated with moving these into major NP production strains 
are discussed. Other areas relevant to NP discovery, including methods of NP identification, 
manipulation of global and pathway-specific regulators, and prioritization of BGCs 
identified via genome sequencing efforts will not be discussed in detail, as these were 
reviewed recently23.
Synthetic biology to accelerate natural product discovery and production
Engineering NP biosynthesis draws tools from a variety of subfields in genetic engineering 
and chemistry. For example, protein engineering seeks to modify the properties of individual 
proteins, including the activity/specificity/stability of enzymes and in the recombination of 
domains to diversify the products of large PKS/NRPS “assembly lines”24. Metabolic 
engineering is focused on understanding how multiple enzymes assemble into a pathway and 
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how this impacts metabolic fluxes in the larger natural network25. For example, the flux of a 
precursor to a natural product could be boosted as part of optimizing the titer. Applied 
microbiology and strain engineering have been critical for identifying high-producing 
organisms and optimizing the titer and performance in a fermentation through processes 
such as the random chemical mutagenesis of the genome26. Synthetic biology has focused 
on tools to accelerate and increase the scale of genetic engineering27,28. The scope of this 
review is to cover recent advances in synthetic biology in the light of how they will impact 
the field of NPs, including the following technologies:
• Abstraction of genetic functions into “parts.” There has been an emphasis 
on creating genetic parts, such as promoters, that generate precise levels of 
gene expression29–32. There has been focus on generating large libraries of 
well-characterized parts and the development of biophysical/
bioinformatics models to predict part behavior33–36. Part libraries for 
different organisms will aid the transfer of BGCs between hosts37–41.
• Large-scale construction technologies. DNA synthesis capacity has 
exploded over the last decade and it is routine to synthesize the 
20kb-100kb needed for a large gene cluster42–44. In addition, new DNA 
assembly methods enable the rapid construction of different part 
permutations or to substitute many parts in a single step45–47.
• Design automation. New computer aided design methods and work 
environments accelerate the process of designing a genetic system, 
scanning the system for errors, and to analyze screening and –omics 
datasets48–50.
• Synthetic regulation. Genetic circuits have been constructed that function 
as logic, timers, switches, and oscillators51–53. Sensors have also been 
developed that respond to many inducible inputs as well as metabolite 
levels. These could be incorporated into natural product pathways to 
control the timing of expression of different genes or to implement 
feedback in response to a toxic intermediate54.
• Genome editing for host design. It is often desirable to make many 
simultaneous genomic changes. Methods, such as CRISPR-Cas9, can 
target essentially any region of the genome and have been shown to 
function in many species, including several host species well-suited for 
industrial production of small molecules55–58.
Reducing genetics to genetic parts
Natural product BGCs are large and unwieldy59. They can comprise several dozen genes, 
arranged in one or many operons facing either direction. Their expression often relies on 
regulatory elements that are overlapping or imbedded in neighboring genes. They are under 
multiple layers of complex regulation including transcriptional and translational control. 
These factors makes engineering gene expression in BGCs technically difficult. This 
organization is in contrast to the concept of ‘genetic parts,’ which are units of DNA with 
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defined and modular function that replace native regulation to provide finer control over 
biological processes60.
Applying a parts-level approach to multi-gene systems is facilitated by ‘refactoring’, in 
which the natural genetics are re-written to make the systems more amenable to engineering 
efforts (Figure 2a)43,61. A refactored gene cluster has several advantages that lend 
themselves to high-throughput applications. First, the process of refactoring severs the native 
regulation, which is usually incompletely understood, and allows for synthetic control of 
gene expression. Second, it leads to a modular genetic architecture, which facilitates part-
swapping and combinatorial optimization. An example of an application would be in the 
creation of diverse compounds by substituting variations of enzymes from homologous 
clusters (Figure 2b). Further, the expression levels of the enzymes are important and it is 
more difficult to control if the regulatory parts (e.g., RBSs) cannot be exchanged without 
leading to a web of other effects. Refactored BGCs can undergo wholesale swapping of 
genetic parts to optimize expression levels and increase titers. The concept of refactoring has 
started to be applied to BCGs62,63 (Figure 2c) around the substitution of some synthetic 
regulatory elements and as the parts and tools improve, this will expand to include the 
complete elimination of native regulation.
Precision control of gene expression
Many metabolic pathways and BGCs are highly sensitive to gene expression, where small 
changes can cause a loss of activity64,65. Recent work to create large libraries of regulatory 
parts enable the graded control of gene expression over many orders of 
magnitude30,33,37,66–68 (Figure 3a). In addition, computational methods have been 
developed that will design a new part based on biophysical models of transcription or 
translation34,35,69,70. While much work has been done in E. coli, there have been efforts to 
expand part libraries into other relevant organisms, including Streptomyces37–39, Bacillus40, 
and fungi41,66,71(Figure 3b). This can often be stymied by issues that are taken for granted in 
model organisms. For example, single cell techniques, such as flow cytometry and 
fluorescent reporters, are difficult to use in Streptomyces because they have multicellular 
branched growth patterns72,73, differences in the DNA copy number, and the stochastic 
nature of gene expression seen during mycelial growth72. Different paradigms for measuring 
part function are needed for these hosts. Part design is also complicated by other issues; for 
example, the high GC content of some genomes make it difficult to codon optimize genes 
and design RNA parts, including RBSs36,74.
In synthetic biology, the concept of the “expression cassette” has been expanded to include 
insulators that increase the reliability of part function in different genetic 
contexts29–32(Figure 3a). This arose out of observations that different combinations of parts, 
for example promoters and RBSs, can lead to unexpected behaviors30,75. Some examples 
include ribozymes that decouple the promoter from the 5′-UTR76 and bi-cistrons that 
decouple the 5′-UTR from the RBS32. These allow the promoters and RBS to be swapped to 
vary expression levels without impacting the behavior of neighboring parts. Similarly, long 
promoters and strong terminators have been developed to transcriptionally insulate the 
genes33,77. Collectively, this has led to genetic architectures that are more focused on the 
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control of individual genes as individual cistrons, as opposed to their organization into 
operons. Adopting these design principles for BGCs will be important for combinatorial 
optimization or in the exchange of parts to create chemical diversity.
High-throughput genetic optimization of multi-gene systems
Accessing new NPs from genome sequence information requires that the BGCs contained in 
sequence databases be converted into physical DNA constructs. High-throughput fabrication 
allows many designs to be tested in parallel, thereby increasing the probability of identifying 
a functional construct. This is beneficial both for chemical diversification via combinatorial 
biosynthesis78–81, as well as for genetic optimization of pathway performance662,64.
There are two DNA construction technologies relevant to BGCs (Figure 4a). The first is de 
novo synthesis where genes or entire clusters are chemically constructed, typically by 
synthesis companies82. The cost has dropped dramatically in the last decade and it is 
possible to order hundreds of individual genes or full clusters43,63,83. While the cost has 
declined significantly, it is still expensive to build large clusters and building comprehensive 
sets of clusters out of the sequence databases is prohibitive. However, for NP biosynthetic 
classes such as RiPPs, this low cost synthetic DNA can be leveraged for combinatorial 
generation of new derivatives84–86.
The second is DNA assembly, which constitutes the combination of parts to build a larger 
construct46,87–94. This enables many variants of gene clusters to be built based on a set of re-
used underlying parts45. This is significantly cheaper that constructing de novo clusters for 
each variant that one wants to test. Many assembly methods are now available, including 
Isothermal assembly91, Golden Gate assembly95, ligase cycling reactions94, scarless 
stitching45, and recombination-based methods92,96. Automating these techniques using 
liquid handling robots enables hundreds or thousands of permuted combinations to be 
built45,48,79,80,85,97.
Combinatorial optimization will be important in optimizing a BCG and transferring it 
between hosts. Epistasis in the expression levels of biosynthetic genes points to the 
importance of combinatorial optimization methods that look at more than one variable at a 
time64,98. Once pathways grow beyond a small handful of genes, complete exploration of 
the combinatorial gene expression space is impractical or impossible. This combinatorial 
space can be reduced via Multivariate Modular Metabolic Engineering by using a priori 
knowledge of a biochemical pathway (e.g., enzyme kinetics, order of reactions, or pathway 
branching architecture) to constrain groups of genes into a small number of operons99. 
Combining metabolic modeling and RBS design, production levels of the isoprenoid 
neurosporene could be tuned over a continuous range from 0-300 μg per gram of dry cell 
weight36. Another approach is to use Design of Experiments (DOE) to reduce the number of 
experiments required to search a combinatorial space. These require that variables effecting 
construct performance can be readily manipulated, but do not require an understanding of 
the underlying biology. Recent examples in the neurosporene and violacein biosynthetic 
pathways shows that following a fractional factorial experiment, new positions in the 
sequence space can be accurately predicted36,71.
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Combinatorial assembly has been applied to the optimization of several NP pathways, as 
well as in the creation of chemical diversity. Several examples of optimizing BGCs, 
including for heterologous production of artimisinin65, taxadiene64, and opiate alkaloids100 
point to the importance of combinatorial engineering, as optimal production levels do not 
result from a blanket gene over-expression. Using a Gibson assembly protocol optimized for 
high GC content, the pathway specific regulators of pristinamycin biosynthesis were 
mutated in a combinatorial fashion to increase production levels to over 1 g/L101. An 
improved three-gene pathway for catechin production was created via combinatorial 
assembly by drawing from eight homologous biosynthetic genes from different plant 
species102. Certain classes of NPs, for example indolocarbazoles, have been greatly 
expanded using combinatorial DNA assembly with more than fifty derivatives created to 
date78,103. Finally, combinatorial assembly has been applied to probe the desire rules 
underlying large multi-modular enzymes79–81,85,104,105. For example, promiscuous 
polyketide donor or accepter modules were identified79.
Host Transfer
Transferring a BGC between hosts is important for NP discovery, diversity screening, and 
optimization. This is particularly true if the BCG only appears in a sequence database and its 
native organism is unknown or inaccessible. Transferring a BCG would enable the new host 
to make the encoded compound.
However, the direct transfer of a BCG between even similar species can result in dramatic 
changes in the timing and relative expression levels for pathway genes (Figures 4c)106. This 
is unsurprising given the performance of genetic parts depends on components of the host 
cell’s machinery75. These host-context effects can result from unintended crosstalk or 
interactions with native regulatory proteins107, from limitations in host resources available 
for expressing heterologous constructs108, and for NP production, from crosstalk with 
endogenous biosynthetic pathways. For example, transfer of the platencin gene cluster from 
S. platensis to the model host S. lividans resulted in the excess accumulation of shunt 
metabolites (Figure 4c,d)106. This was correlated with substantial changes in gene 
expression patterns. A likely explanation is that improperly balanced expression levels in the 
heterologous host led to build-up of pathway intermediates, which were then subject to 
modification by endogenous biosynthetic enzymes and thus diverted away from the desired 
product (Figure 4d). Even moving multi-gene systems just between different strains of the 
same species can likewise negatively impact performance107,109,110.
One way to transfer the BCG more effectively would be to exchange parts for those that are 
known to function in the new species (Figure 4e). Effort could be taken to ensure that the 
desired expression levels are reached in the new host chassis. For example, differences in the 
anti-Shine-Dalgarno sequence in the small ribosomal subunit mean that RBS strengths are 
effected upon transfer to disparate hosts and this requires that all the RBSs be 
simultaneously redesigned36. This type of wholesale reassignment of regulatory parts is 
much easier in refactored genetic systems, whose modular architectures allow them to be 
built up from parts quickly. Also important is increasing the size of characterized part 
libraries for NP-relevant species37–41,66,67,71,90,111,112. For complex multigene systems, the 
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dramatic design changes that accompany host transfer will likely require further genetic 
optimization via combinatorial DNA assembly to re-tune expression levels and improve 
performance (previous section)45.
Genetically-encoded biosensors for biosynthetic pathway engineering
The design and construction of DNA libraries has accelerated to the point where screening 
and making sense of this diversity is the bottleneck. While bioassay-guided prescreens or 
selections can reduce the number of strains that need to be investigated in detail26, these do 
not replace direct measurements of titer. Current analytical chemistry methods have reduced 
analysis time to <3 min per sample113, but this still limits throughput to ~103 per day. As an 
alternative to analytical chemistry, in vivo biosensors translate information about a chemical 
signal, i.e. the concentration of a natural product, into light or fluorescence-based output that 
can be measured by flow-cytometry to screen thousands genotypes per second114. As an 
example of the power of this approach, the inherent fluorescence of the carotenoid 
astaxanthine was exploited to track titers in single cells by flow cytometry and cell-sorting, 
enabling a 10,000-fold enrichment of over-producing strains compared to plate-based 
techniques115.
Intracellular biosensors can be broadly grouped into three categories, RNA-based, protein-
based, or enzyme-based, according to their biomolecular make-up and mechanism. RNA 
aptamers that bind to small molecule signals to actuate a response have been linked to 
readouts including fluorescence, enzyme activity, cell mobility, or viability114,116. There are 
diverse strategies for designing RNA biosensors117–125. RNA aptamers have been used to 
build biosensors for natural products and intermediates, including theophylline121, 
tetracycline124, neomycin126, tobramycin127, dopamine128, and ochratoxin A129.
Protein biosensors function by transmitting molecular binding information into a measurable 
output, usually in the form of allosterically-regulated transcriptional activators or repressors 
controlling fluorescent protein expression. Naturally-evolved biosensors (e.g. Figure 5a,b) 
can detect a wide range of molecular scaffolds, including tetracyclines130,131, cationic lipids 
and plant alkaloids132, and anthraquinones133. There are >4000 TetR proteins identified in 
sequence databases, and only a small fraction of the ligands are known134. While protein 
biosensors have been found or engineered for a number of target molecules, including 
aromatics135,136 and branched-chain amino acids 137, these will need to be repurposed to 
sense new molecules for generalized use in NP discovery and optimization pipelines. Cirino 
and co-workers engineered the transcriptional activator AraC to recognize either mevalonate 
(a key precursor for isoprenoids)138 or triacetic acid lactone (a simple polyketide 
product)139. In an alternative to modulating gene expression, the Liu group has engineered 
protein biosensors that sense small molecule ligands to actuate an intein-splicing 
event140,141, thereby allowing a diverse set of proteins or enzymes to be activated only in the 
presence of the ligand.
Enzymatic biosensors recognize the desired metabolite and convert it into a pigmented or 
fluorescent molecule that can be easily detected by spectrophotometry or flow cytometry. To 
optimize the production of L-DOPA in yeast, Dueber and co-workers expressed a DOPA 
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dioxygenase intracellularly142. The DOPA dioxygenase results in an extradiol ring cleavage 
of L-DOPA to produce the aldehyde-containing betalamic acid, which spontaneously reacts 
with cellular amino acids to form fluorescent imines known collectively as betaxanthins143.
Whole cell biosensors can be created without the need for complicated protein or aptamer 
engineering144. For example, recombinant E. coli made auxotrophic for mevalonate shows 
concentration-dependent growth rate changes in the presence of extracellular mevalonate145. 
By expressing GFP within this strain, mevalonate levels can be detected in high-throughput 
from the culture broths of a production strain145. In principle, this strategy can be used to 
quickly engineer a whole cell biosensor to any molecule that can be made essential for strain 
viability146.
Potential applications for synthetic genetic circuits
The temporal control of expression is often important in building complex chemicals and 
materials147,148. In natural systems, this is implemented via regulatory networks consisting 
of interacting proteins, RNA, and DNA that collectively work to perform a computational 
operation. Synthetic genetic circuits have been built where a target behavior is achieved by 
artificially connecting regulatory proteins (Figure 5). This has been used to build cascades, 
bistable switches, pulse generators, oscillators, feedback/feedforward motifs, and logic 
gates29,51. NP pathways reveal complex and intricate control mechanisms including many of 
these same behaviors149–151. However, the naturally evolved regulation is not required for 
high-level production in defined culture conditions. In fact, its disruption often leads to 
improved production152–154. Replacing native regulation with synthetic circuits may 
implement the necessary feedback and dynamics without also having the environmental 
control that can inhibit production.
Feedback and feedforward regulation has been used to tie the accumulation of early-stage 
pathway intermediates with the expression of downstream processing genes. Feedforward 
regulation is seen in many NP biosynthetic pathways. In actinorhodin biosynthesis, the 
accumulation of pathway intermediates triggers expression of the efflux pump to export the 
final product133. In this case, the feed-forward motif helps to prevent the cell from 
deleterious effects of the accumulating high concentrations of the antibiotic within the cell. 
Modeling of a synthetic pathway for para-aminostyrene biosynthesis suggests that higher 
titers can be attained with dynamic regulation incorporating feedback/feedforward 
regulation compared to static regulation (Figure 5c)155. Using a fatty-acid biosensor to add 
feedforward/feedback regulation into a synthetic fatty acid ester pathway allowed Zhang et 
al. to boost bio-diesel production to 28% theoretical yield (Figure 5d)54. Additionally, 
positive and negative feedback loops can be exploited to control the allocation of cellular 
resources to secondary metabolism (Figure 5e)156.
Synthetic circuits that act as metabolic “control valves” have been used to redirect carbon 
flux from primary to secondary pathways157,158. This dynamic control over central carbon 
metabolism is important, because if this diversion is constitutive, it slows growth to the point 
of decreasing productivity. Similar dynamic switching is seen in Streptomyces prior to 
antibiotic production159. The expression of housekeeping genes, particularly those involved 
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in translation, is strongly diminished prior to entering stationary phase, at which time 
actinorhodin and undecylprodigiosin production begins.
Control over the timing of gene expression can also be achieved using synthetic bistable 
switches, which reset slowly over time (Figure 5f)160. Bistable switches appear in many NP 
producing organisms, including Streptomyces coelicolor where it controls cryptic polyketide 
(cpk) production151. Engineered timing circuits can be used to separate cell growth and NP 
production phases, particularly in strains for which the regulatory connections to the natural 
metabolic switch159 have been severed.
Genetic logic gates allow multiple input signals to be integrated before a pathway turns on. 
There is some evidence of logic in natural NP pathways, for example, the actinorhodin gene 
cluster is controlled by metabolite concentrations, stress response, and development 
program149,150. This can be used to turn on different sets of genes under different 
environmental conditions, the specificity of which improves as more signals are integrated. 
In synthetic biology, many logic gates have been built29,52,107,110,161–163. Connecting 
synthetic multi-input circuits to NP pathways could allow cells to sense cofactor levels, 
precursor abundance, dissolved oxygen content, or ATP charge before deciding whether or 
not to commit to NP biosynthesis. Such intracellular checkpoints could prevent the 
accumulation of unwanted intermediates and byproducts by cells that are not capable of 
making the final product.
CRISPRi has emerged as a powerful method to regulate gene expression, including those in 
the genome, for both prokaryotes and eukaryotes. It is based on the expression of a 
catalytically-inactive dCas9, which can be directed to a target when a sgRNA is 
transcribed164. dCas9 can serve as either a repressor or activator (CRISPRa) depending on 
domains to which it is fused165. CRISPRi has been shown to work in E. coli164, fungi165, 
actinobacteria55, and plants166. Other organisms relevant to NP biosynthesis, such as 
cyanobacteria167, burkholderia168, pseudomonads169, and myxobacteria170, have 
endogenous CRISPR systems but have not as of yet been exploited as hosts for CRISPRi 
regulation. CRISPRi has already been exploited to control metabolic fluxes via multiplexed 
gene repression of endogenous pathways in E. coli171 and in heterologous pathways in yeast 
(Figure 5g)172.
New tools for combinatorial genome-scale engineering
Mutations in the genome outside of the BGC are required to optimize the titers of a NP. 
Some industrial strains can achieve gram per liter quantities, and this is usually achieved via 
random mutagenesis of the genome and screening26. Originally, the genetic diversity was 
generated using techniques such as chemical mutagenesis, but this has gotten more 
sophisticated with improved molecular biology methods. For example, the whole-genome 
shuffling of a tylosin producer yielded the same 6-fold improvement in 24,000 assays that 
had taken Eli Lilly 20 years and 1 million assays to achieve by classical methods173. 
Synthetic biology offers new techniques for generating genome diversity, from methods to 
replace parts or make defined mutations in a multiplexed manner to genome construction via 
de novo synthesis44,174–176.
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Multiplexed genome engineering strategies offer the ability to precisely target hundreds of 
loci in the genome for over- or under-expression in parallel. The first demonstration of 
massively-multiplexed recombineering in E. coli exploited oligo-mediated allelic 
replacement177. By mimicking Okazaki fragments at the replication fork, exogenous 
ssDNAs are able to anneal with the lagging strand of the genome serving as primers for 
DNA elongation and then get incorporated, which leads to simultaneous directed 
mutagenesis at multiple sites in the genome178. MAGE (Multiplexed Automated Genome 
Engineering) automates this process, which allows combinatorial exploration of mutations in 
a continuously evolving population. For example, twenty endogenous E. coli genes were 
targeted to optimize lycopene production and billions of variants were screened177. MAGE 
has also been used to insert regulatory parts into the genome, such as N- and C-terminal 
tags179 and T7 RNAP promoters176,180. Recombineering has been shown to work in diverse 
organisms, including lactic acid bacteria181, mycobacteria182, corynebacteria183, and 
fungi184. Getting MAGE to work in Streptomyces will be challenging due to the high GC-
content, the lack of characterization of mismatch repair in this species, and the fact that the 
expression of some genes required by the technique (e.g., bet) is not likely to produce 
functional proteins183, and transformation is significantly more challenging185. MAGE has 
already been shown to work in yeast and can be applied to pathways transferred to this 
host184 and it may work in other NP-relevant fungi.
TRMR (trackable multiplex recombineering) is a related method, which was developed to 
rapidly map the effects of more than 95% of E. coli genes onto specific traits174. TRMR 
exploits array-based DNA synthesis to create barcoded oligonucleotides that target over 
4,000 genes for either over-expression or repression. Following phenotypic enrichment, 
deep-sequencing allows the targeted mutations to be quickly mapped to identify the causal 
mutations, generating massive amounts of sequence-to-phenotype relationships174,186. 
Combining TRMR with multiplexed recombineering allowed the identification of 27 
genome modification targets that accelerated growth in a target medium186.
CRISPR techniques have revolutionized multiplexed genome engineering55–58,187–197. The 
Cas9 nuclease can be targeted to specific sequences by transcribing a sgRNA (Figure 6a). 
This system has been shown to work in nearly every organism that has been tried, including 
prokaryotes 55,57,171,187,189–191,195 such as Streptomyces (Figure 6b), eukaryotes58,188,198, 
and higher organisms of relevance to NP production56,199. The lack of a canonical non-
homologous end joining (NHEJ) DNA repair in some prokaryotes, including Streptomyces, 
lowers the efficiency of gene inactivation when CRISPR-Cas9 is used alone55,200. However, 
the efficiency of gene inactivation can be increased to over 75% by (i) including a double-
stranded ‘repair fragment’ that can close the double-stranded DNA break via homologous 
recombination57, or (ii) reconstituting a NHEJ pathway through heterologous expression of 
the ligase LigD during genome editing55. This system can be used to make five mutations in 
a single step (Figure 6c)188, knockout 31 kilobase gene clusters57, and insert DNA up to 9 
kilobases in length198.
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Conclusions
New strategies from synthetic biology are enabling the engineering of large systems 
comprising many genetic parts, the control of gene expression with synthetic regulation, and 
efficient genome editing. New tools exist that provide precise control of gene expression 
from synthetic constructs, and the fabrication of large systems is made easier by abstracting 
designs in a parts-based approach to genetic engineering. While many of the approaches in 
this review were developed in a model organism, such as E. coli, over the last few years they 
have been increasingly ported to organisms of more direct relevance to NP discovery and 
production.
For NP chemists and biologists, the challenge will be determining how best to leverage the 
latest technologies in DNA fabrication and genetic control to probe NP pathways in new and 
insightful ways. Much in the same way that recombinant DNA technology revolutionized 
our ability to approach the molecular details of biology from a reductionist point of view, the 
ability to rapidly build large libraries of specifically designed gene clusters will provide 
greater opportunity to explore the effect of genetic design on the functional expression of 
BGCs. Continued research into the detailed regulatory mechanisms of employed within 
natural BGCs and the biochemistry of NP biosynthetic pathways will be paramount for 
forming hypotheses that can be tested using new bottom-up techniques.
Current high-throughput and multiplexed genetic engineering strategies can be harnessed to 
develop applications for NP-producers outside of the fermenter as well (Figure 7). This 
could have applications in environmental sensing, for example producing a small volatile 
metabolite in response to metal contamination in soils, or in the production of therapeutics 
by probiotic strains, for example making antibacterial compounds in response to a pathogen 
in the GI tract201–204. NPs are already used extensively in agriculture for crop protection205, 
and gaining fine-tuned control over production dynamics either in soil microbial 
communities or in crop plants themselves could impact food production.
This is an exciting time for NP biosynthesis. The number of possible applications for NPs in 
medicine, industry, and agriculture is vast. The recent explosion in DNA sequencing 
technologies has revealed that BGCs for NP production are more widespread than 
previously imagined12,19,206, and the ability to ‘write’ DNA into synthetic constructs is now 
catching up. New approaches for mining NPs from genomic sequences are needed more than 
ever to rejuvenate waning drug discovery pipelines, especially in light of the looming crisis 
in antibiotic resistance207. The development of state-of-the-art high-throughput screening 
platforms allow purified compounds or semi-pure extracts to be screened in hundreds of 
assays with less material required than in previous decades208,209. The suite of NPs present 
in nature is one of our most valuable natural resources, and we are now poised to more fully 
explore the extent of its depth and diversity.
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Figure 1. 
Natural product biosynthetic gene clusters. (a) Representation of the diversity of size and 
complexity of NPs and their encoding gene clusters, including tyrvalin, a pyrazinone 
virulence factor from skin-associated staphylococci210, platensimycin, a diterpenoid 
antibiotic from soil-dwelling Streptomyces isolates211, pederin, a polyketide anticancer 
agent produced by an uncultivated symbiont of the Paederus spp. beetles21, and bryostatin, a 
macrocyclic lactone anticancer agent produced by a symbiont of a marine bryozoan212. 
Approximate sizes of BGCs for select NPs (black), along with noteworthy examples of large 
systems that have been built with synthetic DNA technology in wild type (red) or re-
designed (green) genetic architecture. (b) Widening gap of uncharacterized PKS enzymes 
(grey) compared to biochemically characterized PKSs (black) since 2000 (data to 2010 
reproduced from Wong and Khosla213; 2014 data point from Marnix Medema, personal 
communication). Dashed line represents best fit to available data points. (c) Recent history 
of DNA synthesis costs214 and the corresponding number of 50 kb gene clusters that could 
be synthesized with $100k. Dotted lines project to the future along the same trajectory of the 
past 15 years.
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Figure 2. 
Genetic refactoring. (a) Schematic outline of refactoring process, and (b) the streamlined 
refactoring of homologous gene clusters by substituting coding sequences. New homologous 
cluster and corresponding genetic parts are shown in green, and previously refactored cluster 
and parts are shown in blue. Bold lines on chemical structures show conserved core scaffold 
between two enediynes used as a hypothetical example. (c) Refactored epo gene cluster, 
built into a two plasmid system. Extracted ion chromatogram shows production of 
epothilones A and B from the refactored gene cluster introduced to M. xanthus (i), but not 
from the wild-type host (ii)63.
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Figure 3. 
Genetic parts for controlling gene expression levels. (a) Characterization of genetic parts in 
E. coli, including (from left to right), promoter variants30,31, ribosome insulators76, 
bicistronic RBSs32, computationally designed RBSs34, and synthetic and natural 
terminators33. (b) Genetic parts for engineering NP-producing organisms, including 
promoter variants37–39, computationally designed RBSs36, and codon-optimized CDS 
parts74.
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Figure 4. 
Exploiting refactored genetics for host transfer of multi-gene devices. (a) Schematic 
representation of a DNA synthesis and assembly pipeline, wherein genetic parts are 
constructed from synthetic oligonucleotides and then assembled into unique combinations. 
(b) High-throughput library design of permuted gene clusters for antimalarial phosphonate 
FR900098. Bar graph shows characterized titers from constructs selected from iterative 
libraries, with successive libraries from left to right215. (c) Experimental design for 
heterologous expression of ptn gene cluster and RT-PCR results for each operon in native 
and wild-type hosts106. (d) The proposed platencin biosynthetic pathway, along with several 
shunt metabolites isolated from a heterologous expression strain. Values show in red are 
titers in heterologous host, while those shown in green are titers in the native producer. (e) 
Illustration of behavior-matching via part replacement during host transfer. Graphs represent 
empirical characterization of genetic parts in native host (green), and new host (red). 
Landscape graphs show effect on gene clusters performance, as measured by titer of final 
metabolite, in a multivariate system.
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Figure 5. 
Advanced regulation relevant to NP biosynthesis. Examples include (a) inducible promoters 
for NP producing organisms216,217, (b) a mammalian genetic circuit responsive to a bacterial 
metabolite218, (c) dynamic modeling results for a synthetic pathway for para-aminostyrene 
production155, (d) a dynamic feedback/feedforward circuit for monitoring fatty acid ethyl 
ester production in E. coli54, (e) a resource allocation system for controlling transcription of 
a heterologous neurosporene operon in different hosts156, (f) a genetic reset timer for 
controlled sedimentation in yeast160, and (g) multiplexed transcriptional control of the 
violacein biosynthetic pathway using CRISPRi/CRISPRa172. For dynamic modeling 
example (c), graphs show frequencies of expected yields for designs with static regulation 
(top), dynamic regulation (middle), or for the particular pattern of dynamic regulation 
pictured at left (bottom).
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Figure 6. 
Multiplexed genome editing with CRISPR/Cas9. (a) Minimal genome editing construct 
design, including (i) sgRNA, (ii) S. pyogenes Cas9, and (iii) optional ‘repair fragment’. 
Three routes to DNA repair are shown, including homologous recombination (HR, left), 
alternative end-joining (AEJ, center), and non-homologous end-joining (NHEJ, center)195. 
(b) Applications of CRISPR-mediated genome editing in Streptomyces. Graph at bottom 
shows reported efficiencies for experiments grouped by application with background color 
matching illustrations above. Protocol differences are labeled below graph, and data points 
are colored according to published study (blue55, red57, green191). (c) Example of 
multiplexed CRISPR editing for engineering mevalonate levels. Bar graph at bottom shows 
editing efficiency (grey) and mevalonate levels (green), averaged across multiple different 
combinations of gene deletions (number of combinations indicated in parentheses)188.
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Figure 7. 
Diverse applications of engineering NP biosynthesis. Structures of NPs are shown alongside 
a representation of their BGCs with native producing organisms noted.
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